AI assistant
Denali Therapeutics Inc. — Director's Dealing 2019
Jun 13, 2019
31637_dirs_2019-06-12_18826898-b823-46b1-9f6e-1e2fa45fcb8c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Denali Therapeutics Inc. (DNLI)
CIK: 0001714899
Period of Report: 2019-06-10
Reporting Person: Schuth Alexander O. (COO and Secretary)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-06-10 | Common Stock | S | 7500 | $18.77 | Disposed | 632589 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 15738 | Direct |
Footnotes
F1: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
F2: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.49 to $19.24 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee.